Abstract
As thyroid-stimulating immunoglobulins (TSI) are a sign of Graves' disease (GD), measuring TSI titers is becoming increasingly important for GD diagnosis. Only a few studies have assessed the efficacy of TSI detection for diagnosing GD in a Chinese population. This study evaluated the diagnostic accuracy of a new fully automated TSI immunoassay (ImmuliteTM TSI assay) in GD patients and compared it to a thyroid-stimulating hormone receptor antibody (TRAb) immunoassay (ELiATM TRAb assay). Additionally, clinical characteristics associated with responsiveness to methimazole in patients with newly diagnosed GD were preliminarily explored.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
